Aardvark Therapeutics, Inc. Common Stock
AARD · Price history
Price at last available close
$1.51
−$3.76 (-71.35%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Aardvark Therapeutics, Inc. Common Stock
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule.
How they make money
Aardvark Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of novel, small-molecule therapeutics designed to activate innate homeostatic pathways for the treatment of metabolic diseases, with the goal of eventually commercializing these drug candidates.
Products & services
The company's primary product candidate is ARD-101, a small-molecule therapeutic currently in clinical development for the treatment of metabolic diseases, including hypothalamic obesity.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Healthcare providers and patientsSource
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party CROs and CMOs for clinical trial management, data collection, and the manufacturing of drug supplies for clinical studies. Specific supplier names are not disclosed.Source
Strengths
- Proprietary small-molecule therapeutic platform targeting innate homeostatic pathwaysSource
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
29
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
42
Weak
Financial Strength
26
Management
40
Growth Quality
100
Risk / Durability
9
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Model Outlook
12-month model · What does the model think happens next?
Outperformance analysis is not currently available.
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
A current Opportunity Score is not available.
The 12-month model outlook is not currently available.
- •Asset quality scores strongly
- •MAJOR RED FLAG: Reverse split proposed / authorized
- •Valuation is a weaker part of the current profile
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for AARD
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can AARD fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is AARD likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for AARD to reach sustainable profitability?
- •What future growth or profitability would be needed to justify AARD's current valuation?
- •What does the current corporate distress warning mean for the reliability or interpretation of AARD's score?
Essential Investment Snapshot
Wall Street Score
29
Market Cap
$33.0M
P/E Ratio
-0.7
EPS
$-3.21
52-Week High
$16.60
52-Week Low
$1.86
Beta
3.81
Analyst Target
$3.50
Shares Outstanding
21.8M
Total Revenue
$0
Total Debt
$677K
Dividend
No current dividend
Liquidation Value / Share
$3.43
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for AARD
Detected from reported data — verify before acting.MAJOR RED FLAG: Reverse split proposed / authorized
A recent SEC filing discusses authorization, approval, or a proposal for a reverse stock split. This is treated as a major distress/listing-risk signal and caps Wall Street Score below 30 while pending.
Supporting filingCommunity Sentiment
0 active · 0 total callsNo personal call yet on AARD.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary small-molecule therapeutic platform targeting innate homeostatic pathways.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and expectation of future losses.
- −Dependence on the success of a single lead product candidate, ARD-101.
- −Risks associated with clinical trial outcomes and regulatory approval processes.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
30
Oct 1, 2026
Change
+2.3
points
Current Score
33
Oct 23, 2026
Category Changes
AARD increased 2.3 points because Asset improved by 17.8 points.
Positive Contributors
- + Asset improved by 17.8 points
Projected Score
Projected Score
35
Projected Change
+2.0 points
Preliminary comparable-period financial changes suggest improvement of approximately 2.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$1.51
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | ···· |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | ···· |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | ···· |
| Research & Development | $55.1M | $48.9M | $17.4M | $4.5M | ···· |
| SG&A Expenses | $18.9M | $13.8M | $5.3M | $2.2M | ···· |
| Operating Expenses | $74.0M | $62.7M | $22.8M | $7.4M | ···· |
| EBITDA | -$69.8M | -$57.6M | -$22.7M | -$6.6M | ···· |
| Operating Income | -$74.0M | -$62.7M | -$22.8M | -$7.4M | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· |
| Income Before Tax | -$69.9M | -$57.6M | -$20.6M | -$7.2M | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· |
| Net Income | -$69.9M | -$57.6M | -$20.6M | -$7.2M | ···· |
| Basic EPS | $-3.21 | $-2.64 | $-0.95 | $-0.34 | ···· |
| Basic Shares | 21.85M | 21.82M | 21.70M | 21.38M | ···· |
| Diluted Shares | 21.85M | 21.82M | 21.70M | 21.38M | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.66
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+5.0%
Cash Change
+184.1%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
What Weakened
- Debt increased
Potential Score Impact
Positive indicators included cash levels. Pressure indicators included EPS growth, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS was essentially unchanged. Cash increased 184.1%. Total debt increased 5.0%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data
All You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to Buy
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf
Rumor Mill · AARD
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial